[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100469262":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":46,"collaborators":48,"id":52,"slug":20,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":20,"eligibilityCriteria":56,"healthyVolunteers":53,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":20,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":20,"overallStatus":32,"whyStopped":20,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Tildrakizumab treatment","EXPERIMENTAL","Biological\u002Fvaccine: tildrakizumab",[13],"Drug: Tildrakizumab Prefilled Syringe",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Tildrakizumab Prefilled Syringe","IL-23 inhibitor",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Raymond Cho, MD, PhD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","415-575-0524","rashes@ucsf.edu",[31],{"facility":5,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","San Francisco","California","94115","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-122.41942,37.77493,{"lat":42,"lon":41},[45],{"name":23,"role":27,"phone":20,"phoneExt":20,"email":20},{"type":47,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[49],{"name":50,"class":51},"Sun Pharmaceutical Industries Limited","INDUSTRY","100469262",false,"NCT05390515","Psoriatic Immune Response to Tildrakizumab","Inclusion Criteria:\n\n* 18 years of age or older\n* Patients with moderate-severe psoriasis or \\> 5% body surface area affected.\n\nExclusion Criteria:\n\n* taking systemic immunosuppressives in the last 4 weeks\n* pregnancy\n* severe immunodeficiency (either from genetic or infectious causes).\n* tuberculosis or other active serious infection\n* active systemic malignancy.\n* breast-feeding\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.","ALL","18 Years","75 Years",{"count":61,"type":62},10,"ESTIMATED","INTERVENTIONAL",[65],"PHASE4","This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.",[68],"Psoriasis Vulgaris","2026-06-01",{"date":71,"type":72},"2026-06-04","ACTUAL",{"date":74,"type":72},"2022-09-01",{"date":76,"type":62},"2028-09-01",{"name":5,"class":6},1]